Cognition Therapeutics INC 10-Q quarterly reports

Cognition Therapeutics reports on its Q2 2026 financial results, highlighting ongoing clinical trial progress for zervimesine while facing continued operational losses and a need for future funding.

Cognition Therapeutics reports a reduced net loss for Q1 2026, driven by lower R&D expenses, while continuing development of its lead drug candidate, zervimesine.

Cognition Therapeutics reported positive Phase 2 data for zervimesine in DLB and GA, alongside a significant capital raise, extending its cash runway into Q2 2027.

Cognition Therapeutics reported a reduced net loss in Q2 2025, highlighted positive Phase 2 clinical data for zervimesine in Alzheimer's and DLB, and secured funding for a DLB expanded access program, despite ongoing liquidity concerns and Nasdaq compliance challenges.

Cognition Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs targeting age-related degenerative diseases.

Cognition Therapeutics reported its Q3 2024 financial results, highlighting progress in clinical trials but also expressing substantial doubt about its ability to continue as a going concern.

Cognition Therapeutics reported its second quarter 2024 financial results, highlighting ongoing clinical trial progress and a net loss of $16.2 million for the six-month period.

Cognition Therapeutics reported a net loss of $9.2 million for the first quarter of 2024, alongside increased research and development spending and a successful follow-on public offering.